– Reuters
Argus Research Upgrades Comerica to Buy, Announces $87 Price Target
Argus Research analyst Kevin Heal upgrades Comerica (NYSE:CMA) from Hold to Buy and announces $87 price target.
Related Posts
Johnson & Johnson Loses Key Tuberculosis Drug Patent In India, Makes Way For Domestic Generic Players
The Indian Patent Office rejected Johnson and Johnson’s (NYSE:JNJ) application to extend its patent on tuberculosis treatment, bedaquiline, beyond July 2023.…
‘Biggest Upgrade In Siri’s 13-Year History:’ Top Analyst Strikes Bullish Note On Apple Inching Closer To Powering Its Virtual Assistant With OpenAI’s ChatGPT
Top analyst Gene Munster thinks Apple's OpenAI partnership will deliver the "biggest upgrade" in Siri's history.